Ireland: Theravance Biopharma prices US$100.5m US IPO

iStock - ipopba

Dublin-based Theravance Biopharma, a diversified biopharmaceutical company focused on the discovery, development and commercialisation of organ-selective medicines, has priced a US IPO at US$15.00 per share to raise total receipts of around US$100.5m. SVB Leerink and Evercore ISI acted as joint lead bookrunners. Credit Suisse also acted as bookrunner and HC Wainwright was a lead-manager….

You must be a HMI Subscriber to view this content.

Subscribe Now »